avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Company profile
Ticker
ATXI
Exchange
Website
CEO
Lucy Lu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Baergic Bio, Inc. ...
ATXI stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 24
DEF 14C
Information statement
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18 Mar 24
8-K
Other Events
15 Mar 24
PRE 14C
Preliminary information
8 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
8 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
23 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
424B3
Prospectus supplement
2 Feb 24
Latest ownership filings
SC 13D/A
Fortress Biotech, Inc.
17 Apr 24
4
Change in insider ownership
17 Apr 24
4
Change in insider ownership
3 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
Davidow Robert L
13 Dec 23
4
Robert L Davidow
13 Dec 23
SC 13G
Davidow Robert L
28 Nov 23
3
Robert L Davidow
28 Nov 23
SC 13D/A
Fortress Biotech, Inc.
18 Sep 23
4
LINDSAY A MD ROSENWALD
12 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 161.00 k | 161.00 k | 161.00 k | 161.00 k | 161.00 k | 161.00 k |
Cash burn (monthly) | 470.00 k | 4.67 k | 689.33 k | 1.36 mm | 296.33 k | 941.33 k |
Cash used (since last report) | 3.14 mm | 31.15 k | 4.60 mm | 9.09 mm | 1.98 mm | 6.28 mm |
Cash remaining | -2.98 mm | 129.85 k | -4.44 mm | -8.92 mm | -1.82 mm | -6.12 mm |
Runway (months of cash) | -6.3 | 27.8 | -6.4 | -6.6 | -6.1 | -6.5 |
Institutional ownership, Q3 2023
3.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 5 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 149.70 mm |
Total shares | 1.74 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FBIO Fortress Biotech | 1.05 mm | $787.00 k |
CVI Investments | 251.01 k | $0.00 |
Intracoastal Capital | 216.79 k | $616.00 k |
Geode Capital Management | 52.57 k | $37.00 mm |
BK Bank Of New York Mellon | 51.57 k | $36.46 mm |
Vanguard | 46.29 k | $32.73 mm |
STT State Street | 30.59 k | $21.53 mm |
Two Sigma Securities | 14.44 k | $10.21 mm |
Shikiar Asset Management | 12.50 k | $9.00 k |
Tower Research Capital | 6.88 k | $4.86 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 413,507 | 0.00 | 3,547,393 |
2 Jan 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 2,101,496 | 0.00 | 3,133,886 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | Yes | No | 0.14 | 20,000 | 2.80 k | 80,000 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | Yes | No | 0.14 | 128,000 | 17.92 k | 147,000 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | Yes | No | 0.14 | 126,000 | 17.64 k | 215,800 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | Yes | No | 0.14 | 61,000 | 8.54 k | 74,000 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | Yes | No | 0.15 | 18,000 | 2.70 k | 22,000 |
11 Dec 23 | Robert L Davidow | Common Stock | Sell | Dispose S | No | No | 0.14 | 264,000 | 36.96 k | 681,000 |
8 Sep 23 | Fortress Biotech | Common Stock | Buy | Acquire P | No | No | 0.72 | 418,410 | 301.26 k | 1,032,390 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Apr 24
Avenue Therapeutics Q4 EPS $(0.98) Misses $(0.10) Estimate
18 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Mar 24
Press releases
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
25 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
18 Mar 24
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
15 Mar 24
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
11 Mar 24
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
22 Feb 24